The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•2 March 2026•

1 min read

Ginkgo Bioworks Pivots Strategy After Q4 Revenue Miss and Growth Shortfall

A man in a suit over a stock chart with 'Mondelez International' text, surrounded by chocolate, cocoa beans, factories, and shops.

Key Facts

1Q4 revenues reached $33 million, down 24% year-over-year, missing estimates by over $4 million.

2The Cell Engineering segment delivered $125 million in 2025 revenue, far below the original SPAC projection of $1.1 billion.

Ginkgo Bioworks (DNA) reported disappointing fourth-quarter results, with revenues reaching $33 million, a 24% decline year-over-year. The reported figures missed analyst estimates by more than $4 million, highlighting significant operational headwinds for the biotech firm. The company's Cell Engineering segment delivered $125 million in 2025 revenue, falling drastically short of the $1.1 billion projection originally set during its SPAC merger. In response to these challenges, management announced a major strategic pivot involving the sale of its Biosecurity business segment. Ginkgo plans to retain only a minority stake in the newly formed private entity as it seeks to restructure its struggling business model. This restructuring follows a period of sustained underperformance and a failure to meet the aggressive growth targets established during its public debut.